Department of Obstetrics and Gynecology, Division of Prenatal Medicine, University Hospital Giessen and Marburg, Campus Giessen, Justus-Liebig University, Giessen, Germany.
Fetal Cardiology Unit, Ukrainian Children's Cardiac Center, Kyiv, Ukraine.
Prenat Diagn. 2017 Aug;37(8):812-819. doi: 10.1002/pd.5094. Epub 2017 Jul 12.
The objective of this study was to analyze the spectrum of prenatally diagnosed absent pulmonary valve syndrome (APVS) and the outcome from diagnosis onwards. Fetuses with APVS and tetralogy of Fallot (TOF/APVS) and with APVS and intact ventricular septum (APVS/IVS) were included.
Multicenter retrospective study of the International Prenatal Cardiology Collaboration Group. Clinical and echocardiographic databases of nine referral centers were reviewed from 2012-2016.
The cohort included 71 cases, 59 with TOF/APVS and 12 with APVS/IVS. In 18.3% of cases, diagnosis was achieved within first trimester. Association with hydrops fetalis was high within first trimester (69%). No fetus with known outcome survived after first trimester diagnosis. Karyotype anomalies occurred in 45% of cases with known karyotype. Intrauterine fetal demise occurred in 14.3%. Overall survival after initial diagnosis in the total cohort was 28.1% (28.8% TOF/APVS and 25.0% APVS/IVS). Survival to birth was 50% in TOF/APVS and 44.4% in APVS/IVS. Survival of subjects born alive beyond neonatal period was 84.6% in TOF/APVS and 100% in APVS/IVS.
Diagnosis of APVS is feasible within first trimester. Outcomes remain guarded, especially if first trimester diagnosis is included into the analysis because of associated karyotypic anomalies, the presence of hydrops fetalis, and patent ductus arteriosus. © 2017 John Wiley & Sons, Ltd.
本研究旨在分析产前诊断的肺动脉瓣缺如综合征(APVS)的谱,并从诊断开始分析其预后。纳入的病例包括 APVS 合并法洛四联症(TOF/APVS)和 APVS 合并完整室间隔(APVS/IVS)。
国际产前心脏病学协作组的多中心回顾性研究。对 9 个转诊中心的临床和超声心动图数据库进行了 2012-2016 年的回顾性分析。
该队列包括 71 例患者,59 例为 TOF/APVS,12 例为 APVS/IVS。在 18.3%的病例中,在孕早期即做出诊断。在孕早期,与胎儿水肿的相关性很高(69%)。在孕早期诊断后,无已知结局的胎儿存活。已知核型的病例中有 45%发生核型异常。胎儿宫内死亡发生率为 14.3%。在总队列中,初始诊断后的总体生存率为 28.1%(TOF/APVS 为 28.8%,APVS/IVS 为 25.0%)。TOF/APVS 组的活产生存率为 50%,APVS/IVS 组为 44.4%。存活至新生儿期后的患儿,TOF/APVS 组的生存率为 84.6%,APVS/IVS 组为 100%。
APVS 的诊断可在孕早期实现。预后仍不容乐观,尤其是在包括早期诊断在内的分析中,因为这与核型异常、胎儿水肿和动脉导管未闭的存在有关。 © 2017 约翰威立父子公司